CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 177 filers reported holding CRINETICS PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 0.81 and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $84,839,893 | +110.4% | 2,852,720 | +27.5% | 0.01% | +150.0% |
Q2 2023 | $40,323,985 | +13.2% | 2,237,735 | +0.9% | 0.00% | 0.0% |
Q1 2023 | $35,633,832 | -51.4% | 2,218,794 | -44.7% | 0.00% | 0.0% |
Q4 2022 | $73,375,094 | +106.6% | 4,009,568 | +121.7% | 0.00% | 0.0% |
Q3 2022 | $35,522,000 | +8.2% | 1,808,665 | +2.7% | 0.00% | 0.0% |
Q2 2022 | $32,840,000 | -12.0% | 1,760,845 | +3.5% | 0.00% | 0.0% |
Q1 2022 | $37,330,000 | +1.0% | 1,700,679 | +30.8% | 0.00% | 0.0% |
Q4 2021 | $36,944,000 | +57.3% | 1,300,374 | +16.5% | 0.00% | +100.0% |
Q3 2021 | $23,489,000 | +128.0% | 1,115,859 | +104.2% | 0.00% | 0.0% |
Q2 2021 | $10,300,000 | +42.6% | 546,432 | +15.6% | 0.00% | – |
Q1 2021 | $7,221,000 | +6.4% | 472,561 | -1.7% | 0.00% | – |
Q4 2020 | $6,784,000 | -2.4% | 480,799 | +8.3% | 0.00% | – |
Q3 2020 | $6,954,000 | -5.3% | 443,775 | +5.9% | 0.00% | -100.0% |
Q2 2020 | $7,340,000 | +122.4% | 418,975 | +86.6% | 0.00% | – |
Q1 2020 | $3,300,000 | -42.0% | 224,494 | -0.9% | 0.00% | – |
Q4 2019 | $5,685,000 | +83.2% | 226,601 | +9.8% | 0.00% | – |
Q3 2019 | $3,103,000 | -39.0% | 206,296 | +1.3% | 0.00% | – |
Q2 2019 | $5,091,000 | +112.2% | 203,628 | +93.2% | 0.00% | – |
Q1 2019 | $2,399,000 | -22.4% | 105,399 | +2.2% | 0.00% | – |
Q4 2018 | $3,093,000 | +41.3% | 103,148 | +35.0% | 0.00% | – |
Q3 2018 | $2,189,000 | – | 76,379 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Saturn V Capital Management LP | 1,126,579 | $33,504,459 | 14.02% |
New Leaf Venture Partners, L.L.C. | 141,000 | $4,193,340 | 5.38% |
First Light Asset Management, LLC | 1,583,329 | $47,088,204 | 4.47% |
Paradigm Biocapital Advisors LP | 2,178,737 | $64,795,638 | 4.40% |
Bain Capital Life Sciences Investors, LLC | 1,275,552 | $37,934,916 | 4.24% |
Altium Capital Management LP | 262,000 | $7,791,880 | 4.06% |
5AM Venture Management, LLC | 462,286 | $13,748,386 | 3.96% |
MPM BioImpact LLC | 479,053 | $14,247,036 | 3.80% |
Affinity Asset Advisors, LLC | 450,000 | $13,383,000 | 3.76% |
Opaleye Management Inc. | 370,000 | $11,003,800 | 3.58% |